Masimo delivered Q3 results that mostly aligned with guidance, yet it faces challenges in its non-healthcare segment.

Separately, a Delaware jury in late October found that Masimo’s current products did not infringe any of Apple’s patents. The ...

Shares of Masimo Co. (NASDAQ:MASI – Get Free Report) have received an average rating of “Moderate Buy” from the seven ...

Executives said the patient monitoring company’s consumer business will likely become a discontinued operation if it is not ...

A Delaware jury has ruled in favor of Apple Inc. (NASDAQ:AAPL) in a patent infringement case against Masimo Corp.

Masimo (Nasdaq:MASI) shares ticked up before hours today on third-quarter results that came in ahead of the consensus ...

that one of Apple’s technology patent claims is invalid and that no current Masimo product infringed any of Apple’s design patents,” said a statement from Masimo. “Although the jury found that a ...

markets sells and licenses premium and luxury audio sound products and related integration technologies. Understanding the Numbers: Masimo's Finances Market Capitalization Analysis: The company's ...

“Apple primarily sought an injunction against Masimo’s current products, and the jury’s verdict is a victory for Masimo on that issue,” Masimo said. Apple said in a statement that it was ...

Revenue: US$504.6m (up 5.4% from 3Q 2023). Net income: US$9.80m (down 7.5% from 3Q 2023). Profit margin: 1.9% (down from 2.2% in 3Q 2023). The decrease in margin was driven by higher expenses. EPS ...

Young said Masimo is lowering corporate overhead costs, with cuts such as selling the corporate jet and reducing marketing expenses for products that aren't producing meaningful revenue and returns.

Masimo MASI is set to give its latest quarterly ... remote monitoring devices and consumer health products. Its non-healthcare segment includes consumer audio business develops, manufactures ...